Bicara Therapeutics宣布,其药物Ficerafusp Alfa已获得美国食品药品监督管理局(FDA)授予的突破性疗法认定,用于治疗一线HPV阴性复发/转移性头颈部鳞状细胞癌患者。
这一认定标志着该公司在头颈部癌症治疗领域取得的重要监管里程碑,有望为患者提供新的治疗选择。
Bicara Therapeutics宣布,其药物Ficerafusp Alfa已获得美国食品药品监督管理局(FDA)授予的突破性疗法认定,用于治疗一线HPV阴性复发/转移性头颈部鳞状细胞癌患者。
这一认定标志着该公司在头颈部癌症治疗领域取得的重要监管里程碑,有望为患者提供新的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.